Know what's inside:
LKF expands lab services with the cobas® 6800 system
23.8.2022

LKF expands lab services with the cobas® 6800 system

To address the rapidly growing need in scalable und fully automated Polymerase Chain Reaction (PCR) based Nucleic Acid Testing (NAT) LKF expands its assay portfolio with the cobas® 6800 system.

Dr. rer.nat. M. Heise (Lab manager):
Besides SARS-CoV (COVID-19) testing a wide range of respiratory virus and bacteria testing is now available. On site confirmation testing (e.g. HIV, Hepatitis virus) reduces the turnaround time in reporting.

Dr. med. G. Schönicke (Managing director):
LKF is well prepared to address the current and future needs of sponsors in clinical trials. New challenges like high-throughput testing for the detection of monkey poxvirus can be offered for clinical trials on demand.

If you want more information and how we can support your clinical trial as a central laboratory, please contact Christian Klauke at bd@lkf-kiel.de.

© 2022 GBA Group

Follow Us

  • linkedIn GBA Pharma
  • xing
  • GBA youtube
  • gba Instagram
ContactData PrivacyLegal NoticeTerms & ConditionsDisclosure
Phone Phone
Tel.
Jobs
Jobs